NUTRITIONAL COMPOSITIONS COMPRISING SN-1(3) MONOACYLGLYCEROLS FOR USE IN THE TREATMENT OF GROWTH DELAY IN INFANTS OR CHILDREN
The present invention refers to nutritional composition comprising sn-1(3) monoacylglycerols for use in the prevention/treatment of growth delay and/or in the promotion of growth in an infant or in a child like a young child, such as a preterm and/or low birth weight infants.
1 . A method for the prevention/treatment of growth delay and/or in the promotion of growth in an infant or a child comprising administering a nutritional composition comprising sn-1(3) monoacylglycerols to an individual in need of same.
2 . Method according to claim 1 , wherein the sn-1(3)-monoacylglycerol is selected from the group consisting of sn-1(3)-monohexadecanoylglycerol, sn-1(3)-monotetradecanoylglycerol, sn-1(3)-monoeicosatetraenoilglycerol, sn-1(3)-monooctadecanoylglycerol, sn-1(3)-monooctadecadienoylglycerol, sn-1(3)-monoeicosapentaenoylglycerol, sn-1(3)-mono docosahexaenoylglycerol, sn-1 (3)-monooctadecatrienoylglycerol, sn-1(3)-monooctadecatetraenoylglycerol, sn-1(3)-monoeicosatrienoylglycerol, sn-1(3)-monodocosapentaenoylglycerol, sn-1(3)-monosciadonylglycerol, sn-1(3)-monojuniperonylglycerol and combinations thereof.
3 . Method according to claim 1 , wherein the sn-1(3)-monoacylglycerol is selected from the group consisting of sn-1(3) monoeicosapentaenoylglycerol, sn-1(3)-mono docosahexaenoylglycerol, sn-1(3)-monoeicosatetraenoilglycerol, sn-1(3)-monooctadecadienoylglycerol, sn-1(3)-monooctadecatrienoylglycerol and combinations thereof.
4 . Method according to claim 1 , wherein the sn-1(3) monoacylglycerol provides from 0.0001% to 100% of the energy of the nutritional composition.
5 . Method according to claim 1 , wherein the sn-1(3) monoacylglycerols comprises at least one functional fatty acid.
6 . Method according to claim 5 , wherein the functional fatty acid is selected from the group consisting of tetradecanoic acid (myristic acid), hexadecanoic acid (palmitic acid), octadecanoic acid (stearic acid), eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), alpha-linolenic acid (ALA), linoleic acid (LA), arachidonic acid (ARA), stearidonic acid (SA), γ-linolenic acid (GLA), dihomo-γ-linolenic acid (DGLA), n-3 docosapentanenoic acid (DPA), sciadonic acid and juniperonic acid.
7 . Method according to claim 1 , wherein the sn-1(3) monoacylglycerols (MAG) comprise at least one of sn-1(3) MAG-EPA, sn-1(3) MAG-DHA, sn-1(3) MAG-LA, sn-1(3) MAG-ALA or sn-1(3) MAG-ARA.
8 . Method according to claim 1 , wherein growth refers to the size of the infant or child and/or to any organ or tissue development of the infant or child.
9 . Method according to claim 1 , wherein fat absorption in an infant or a child is improved.
10 . Method according to claim 1 for use in the promotion of bone's growth and quality in an infant or a child.
11 . Method according to claim 1 for use in the cognitive development, the motor and/or the behavioural development in an infant or a child.
12 . Method according to claim 1 for use in the visual acuity development and/or the reduction of ROP risks in an infant or a child.
13 . Method according to claim 1 for use in the lung development and/or the reduction of BPD risks in an infant or a child.
14 . Method according to claim 1 for use in the cardiovascular system health and development in an infant or a child.
15 . (canceled)
16 . Method according to claim 1 wherein the infant or the child was born preterm and/or is small for gestational age (SGA) and/or has/had a low birth weight and/or is sick.
17 . (canceled)
18 . Method according to claim 1 , wherein the nutritional composition is in a form selected from the group consisting of an infant formula, a starter infant formula, a follow-up or a follow-on infant formula, a growing-up milk, a baby food, an infant cereal composition, a fortifier and a supplement.
19 . Method according to claim 1 , wherein the nutritional composition comprises a protein source, a carbohydrate source and a lipid source.
20 . A method for providing nutrition to an infant or a child comprising administering to the infant or child sn-1(3) monoacylglycerols in a nutritional composition.
21 . Method according to claim 20 , wherein the sn-1(3) monoacylglycerols is selected from the group consisting of sn-1(3)-monohexadecanoylglycerol, sn-1(3)-monotetradecanoylglycerol, sn-1(3)-monoeicosatetraenoilglycerol, sn-1(3)-monooctadecanoylglycerol, sn-1(3)-monooctadecadienoylglycerol, sn-1(3)-monoeicosapentaenoylglycerol, sn-1(3)-mono docosahexaenoylglycerol, sn-1(3)-monooctadecatrienoylglycerol, sn-1(3)-monooctadecatetraenoylglycerol, sn-1(3)-monoeicosatrienoylglycerol, sn-1(3)-monodocosapentaenoylglycerol, sn-1(3)-monosciadonylglycerol, sn-1(3)-monojuniperonylglycerol and combinations thereof.
22 . Method according to claim 20 wherein the infant or child is preterm and/or low birth weight.